The impact of inflammation and cytokine expression of PM2.5 in AML

Oncology Letters
Tingting ChenHebing Zhou

Abstract

Environmental and health issues have become a major focus of research worldwide in recent years. Particulate matter with diameter ≤2.5 µm (PM2.5) is a common air pollutant that has been demonstrated to be associated with various diseases, including acute myeloid leukemia (AML). In the present study, the effects of PM2.5 on the proliferation and inflammation were assessed using three human acute myeloid cell lines (U937, HL-60 and KG-1a) in vitro. Additionally, the levels of several cytokines [interleukin (IL)-2, IL-10, IL-17A and tumor necrosis factor (TNF)α] in AML cells and Sprague Dawley rats were evaluated to investigate the effects of PM2.5 on cytokine expression in AML. The results revealed that PM2.5 was capable of enhancing inflammatory responses in AML cells, and increasing IL-2, IL-10, IL-17A and TNFα mRNA expression in AML cells to different degrees. Furthermore, PM2.5 increased IL-2 and IL-10 contents in rats following 12 weeks of exposure. These results suggested that PM2.5 may serve a role in promoting the occurrence and progression of leukemia by affecting cytokine expression, and that there may be various mechanisms active in different AML subtypes.

References

Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Oct 29, 2002·Lancet·Bert Brunekreef, Stephen T Holgate
Nov 2, 2002·Blood·Muneo NumasakiMichael T Lotze
Jan 30, 2004·Cytokine & Growth Factor Reviews·Simone MocellinMario Lise
Oct 13, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Alpana SharmaManoj Sharma
Feb 22, 2011·Protein & Cell·Xiaoping ZhangHong Tang
Sep 8, 2011·Journal of Cellular and Molecular Medicine·Yi WangXizhong Shen
Nov 30, 2011·Cancer Research·Takashi TanikawaWeiping Zou
Dec 17, 2011·Cancer Cell·John B MummMartin Oft
Mar 6, 2013·The Journal of Pathology·John P WatersJohn R Bradley
May 21, 2014·The Journal of Experimental Medicine·Andrew VolkJiwang Zhang
Jan 20, 2015·Current Opinion in Immunology·Sharad K Mittal, Paul A Roche
Feb 6, 2015·Frontiers of Medicine·Lei HanBin Li
Mar 25, 2015·Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis & Ecotoxicology Reviews·Tommaso FilippiniMarco Vinceti
Jun 20, 2015·Drug Design, Development and Therapy·Xiao-Wu Chen, Shu-Feng Zhou
Jul 21, 2015·International Journal of Environmental Research and Public Health·Chenchen WangRongzhu Lu
Sep 20, 2015·Biochimica Et Biophysica Acta·Bijender KumarChing-Cheng Chen
Sep 29, 2015·International Journal of Cancer. Journal International Du Cancer·Ole Raaschou-NielsenMette Sørensen
Oct 22, 2015·Archives of Toxicology·Xiao-Ting JinZhuo-Yu Li
Jan 13, 2016·Occupational and Environmental Medicine·Aileen YangUlrike Gehring
Feb 18, 2016·Cancer Research·Franck HousseauCynthia L Sears
Apr 12, 2016·International Journal of Cancer. Journal International Du Cancer·Rushikesh Sudam PatilShubhada Vivek Chiplunkar
Nov 25, 2016·Journal of Neuroinflammation·Diogo Lobo-SilvaMargarida Saraiva
Jun 21, 2017·International Journal of Environmental Research and Public Health·Angelo G Solimini, Matteo Renzi
Oct 27, 2017·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Zongqiang HuLi Li
Feb 23, 2018·The European Respiratory Journal·Anke HülsTamara Schikowski

❮ Previous
Next ❯

Citations

May 20, 2021·Environmental Science and Pollution Research International·Tong WeiFen Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.